{
    "clinical_study": {
        "@rank": "79100", 
        "arm_group": [
            {
                "arm_group_label": "Faster-acting insulin aspart", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be allocated to two treatments (in random sequence)."
            }, 
            {
                "arm_group_label": "NovoRapid\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Each subject will be allocated to two treatments (in random sequence)."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the\n      pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect\n      of the investigated drug on the body) properties of faster-acting insulin aspart in subjects\n      with Type 1 diabetes."
        }, 
        "brief_title": "A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18-64 years (both inclusive) at the time of signing informed consent\n\n          -  Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months\n\n          -  Body mass index 18.5-28.0 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Subject who has donated any blood or plasma in the past month or more than 500 mL\n             within 3 months prior to screening\n\n          -  Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe\n             daily)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02131246", 
            "org_study_id": "NN1218-3921", 
            "secondary_id": [
                "2013-002890-23", 
                "U1111-1145-0195"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Faster-acting insulin aspart", 
                "description": "Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid\u00ae at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)", 
                "intervention_name": "Faster-acting insulin aspart", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NovoRapid\u00ae", 
                "description": "Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid\u00ae at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 6, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Graz", 
                    "country": "Austria", 
                    "zip": "8036"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean plasma glucose concentration", 
            "safety_issue": "No", 
            "time_frame": "From 0\u22126 hours after start of a standardised meal"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02131246"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Area under the serum insulin aspart concentration-time curve", 
            "safety_issue": "No", 
            "time_frame": "From 0 to 12 hours after trial product administration"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}